Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR12202487

—

2617c930-e525-533d-bdfe-6d826a6c16ac

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.380
  • MYC_TARGETS_V1+0.340
  • PANCREAS_BETA_CELLS+0.290
  • HYPOXIA+0.280
  • COAGULATION+0.230
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
  • TGF_BETA_SIGNALING+0.190
  • APICAL_JUNCTION+0.170
  • GLYCOLYSIS+0.170
  • NOTCH_SIGNALING+0.170

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.480
  • INTERFERON_GAMMA_RESPONSE-0.420
  • IL6_JAK_STAT3_SIGNALING-0.350
  • DNA_REPAIR-0.310
  • ALLOGRAFT_REJECTION-0.240
  • INFLAMMATORY_RESPONSE-0.210
  • OXIDATIVE_PHOSPHORYLATION-0.210
  • E2F_TARGETS-0.200
  • G2M_CHECKPOINT-0.200
  • MITOTIC_SPINDLE-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2208919
melanoma-umap@29
——0.756
2TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.748
3SRR11296891
colon-landscapes@1
——0.743
4eaecaea1-2cb7-472c-b549-ff779e5e1d30
melanoma-umap@29
——0.719
520ed86b0-2e3d-44ec-88cd-eac5486fe15c
colon-landscapes@1
——0.718
6MBCProject_6246_T1_RNA
breast-umap@18
—C0.714
7SRR2932826
head-neck@1
——0.713
8a7bda5b9-9c95-4f90-bab6-10ab15ee2b48
melanoma-umap@29
——0.713
9SRR2932825
head-neck@1
——0.712
10350f38a2-e597-494a-a387-975814453726
melanoma-umap@29
——0.703

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.380Remibrutinib— uncovered
MYC_TARGETS_V10.340Inavolisib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
HYPOXIA0.280Idelalisib— uncovered
COAGULATION0.230Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.230Inavolisib— uncovered
TGF_BETA_SIGNALING0.190Inavolisib— uncovered
APICAL_JUNCTION0.170Inavolisib— uncovered
GLYCOLYSIS0.170Inavolisib— uncovered
NOTCH_SIGNALING0.170Inavolisib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
MTORC1_SIGNALING0.130Inavolisib— uncovered
MYOGENESIS0.130Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.120Inavolisib— uncovered
MYC_TARGETS_V20.100Idelalisib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.090Inavolisib— uncovered
ANDROGEN_RESPONSE0.080Inavolisib— uncovered
P53_PATHWAY0.080Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.080Idelalisib— uncovered